Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

[1]  Y. She,et al.  N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer , 2021, Molecular cancer.

[2]  Lei Wang,et al.  LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22 , 2021, Frontiers in Cell and Developmental Biology.

[3]  Jianlong Li,et al.  Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy. , 2021, Biochemical and biophysical research communications.

[4]  Fang Wang,et al.  Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression , 2021, Advanced science.

[5]  Minhua Liang,et al.  Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[6]  Jinfang Zhang,et al.  Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1 , 2020, Cell Death & Differentiation.

[7]  Hong-min Liu,et al.  Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing , 2020, Acta pharmaceutica Sinica. B.

[8]  Yan Wang,et al.  KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression , 2020, Proceedings of the National Academy of Sciences.

[9]  N. Tang,et al.  2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1 , 2020, Journal for ImmunoTherapy of Cancer.

[10]  Bo Xu,et al.  Rho‐associated protein kinase‐dependent moesin phosphorylation is required for PD‐L1 stabilization in breast cancer , 2020, Molecular oncology.

[11]  Gang Wu,et al.  USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer , 2020, Theranostics.

[12]  S. Fan,et al.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells , 2020, Cell Communication and Signaling.

[13]  M. Yin,et al.  Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 , 2020, Acta pharmaceutica Sinica. B.

[14]  Yuhe Wu,et al.  KLHL22 Regulates the EMT and Proliferation in Colorectal Cancer Cells in Part via the Wnt/β-Catenin Signaling Pathway , 2020, Cancer management and research.

[15]  A. Clark,et al.  SPOP and cancer: a systematic review. , 2020, American journal of cancer research.

[16]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[17]  M. Ma,et al.  USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin , 2020, Irish Journal of Medical Science (1971 -).

[18]  Hong Wang,et al.  Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells , 2020, Journal of Experimental & Clinical Cancer Research.

[19]  X-H Zhang,et al.  MiR-135b-5p inhibits the progression of malignant melanoma cells by targeting RBX1. , 2020, European review for medical and pharmacological sciences.

[20]  G. Duan,et al.  E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation , 2020, Molecular and Cellular Biology.

[21]  Yichi Xu,et al.  The emerging role of SPOP protein in tumorigenesis and cancer therapy , 2020, Molecular Cancer.

[22]  B. Stanger,et al.  Tumor Cell–Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer , 2019, Cancer Immunology Research.

[23]  Bangshun He,et al.  Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway , 2019, Cell Death & Differentiation.

[24]  Mostafa E. Belghasem,et al.  c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth , 2019, Scientific Reports.

[25]  I. Dikic,et al.  Cellular quality control by the ubiquitin-proteasome system and autophagy , 2019, Science.

[26]  Yonghong Sun,et al.  Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer. , 2019, Cancer research.

[27]  Qiaojun He,et al.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses , 2019, Acta pharmaceutica Sinica. B.

[28]  D. Tang,et al.  STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling , 2019, Cancer science.

[29]  Xing Huang,et al.  USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity , 2019, Cancer Immunology Research.

[30]  Liang Deng,et al.  Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation , 2019, Oncogene.

[31]  C. Das,et al.  Uncovering the Structural Basis of a New Twist in Protein Ubiquitination. , 2019, Trends in biochemical sciences.

[32]  I. Bezsonova,et al.  USP7: Structure, substrate specificity, and inhibition. , 2019, DNA repair.

[33]  P. Nghiem,et al.  Faculty Opinions recommendation of Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[34]  C. Curran,et al.  PD-1 immunobiology in systemic lupus erythematosus. , 2019, Journal of autoimmunity.

[35]  R. Pulido,et al.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma , 2019, Current Urology Reports.

[36]  M. Yao,et al.  DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up‐regulates PD‐L1 in non‐small‐cell lung cancer , 2019, Experimental cell research.

[37]  Min Zhang,et al.  MiR‐940 promotes the proliferation and migration of gastric cancer cells through up‐regulation of programmed death ligand‐1 expression , 2018, Experimental cell research.

[38]  Wei Yang,et al.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells , 2018, Nature.

[39]  Zhining Fan,et al.  Upregulation of HRD1 promotes cell migration and invasion in colon cancer , 2018, Molecular and Cellular Biochemistry.

[40]  Zhaojian Liu,et al.  HRD1-mediated PTEN degradation promotes cell proliferation and hepatocellular carcinoma progression. , 2018, Cellular signalling.

[41]  P. Dong,et al.  Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion , 2018, Front. Oncol..

[42]  Shaoru Li,et al.  MicroRNA-302 inhibits cell migration and invasion in cervical cancer by targeting DCUN1D1. , 2018, Experimental and therapeutic medicine.

[43]  W. Symmans,et al.  Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. , 2018, Molecular cell.

[44]  Zhou Aiping,et al.  Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin‐specific peptidase 9, X‐linked in oral squamous cell carcinoma , 2018, Cancer medicine.

[45]  J. Huo,et al.  F-box proteins involved in cancer-associated drug resistance. , 2018, Oncology letters.

[46]  J. Meza,et al.  Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. , 2018, Cancer research.

[47]  Yuntao Xie,et al.  KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing , 2018, Nature.

[48]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[49]  Ce Li,et al.  E3 ubiquitin ligases Cbl‐b and c‐Cbl downregulate PD‐L1 in EGFR wild‐type non‐small cell lung cancer , 2018, FEBS letters.

[50]  J. Taube,et al.  PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[51]  Arash Salmaninejad,et al.  PD-1 and cancer: molecular mechanisms and polymorphisms , 2018, Immunogenetics.

[52]  N. H. Nagoor,et al.  MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively , 2018, Journal of Cancer.

[53]  Y-S Wang,et al.  Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells. , 2017, European review for medical and pharmacological sciences.

[54]  S. Dawson,et al.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.

[55]  S. Staibano,et al.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma , 2017, Oncotarget.

[56]  A. Surolia,et al.  Role of glycosylation in nucleating protein folding and stability. , 2017, The Biochemical journal.

[57]  H. Horlings,et al.  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators , 2017, Nature.

[58]  K. Manova,et al.  Squamous cell carcinoma–related oncogene (SCCRO) neddylates Cul3 protein to selectively promote midbody localization and activity of Cul3KLHL21 protein complex during abscission , 2017, The Journal of Biological Chemistry.

[59]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[60]  Y. Shang,et al.  USP9X regulates centrosome duplication and promotes breast carcinogenesis , 2017, Nature Communications.

[61]  P. Pandolfi,et al.  Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones , 2017, Oncotarget.

[62]  Peter C. Hollenhorst,et al.  Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma , 2017, Nature Communications.

[63]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[64]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[65]  R. Clark,et al.  Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation , 2017, Front. Immunol..

[66]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[67]  Wei Wang,et al.  A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer , 2016, Medicine.

[68]  Arash Salmaninejad,et al.  PD-1/PD-L and autoimmunity: A growing relationship. , 2016, Cellular immunology.

[69]  D. Sterner,et al.  Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity , 2016, EBioMedicine.

[70]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[71]  S. Wood,et al.  Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines , 2016, Cell proliferation.

[72]  Jianxun Song,et al.  The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity , 2016, Nature Communications.

[73]  Junnian Zheng,et al.  The emerging roles of Jab1/CSN5 in cancer , 2016, Medical Oncology.

[74]  A. Satelli,et al.  Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients , 2016, Scientific Reports.

[75]  Y. Shang,et al.  Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. , 2016, The Journal of clinical investigation.

[76]  Chuan-chao He,et al.  Regulation mechanism of Fbxw7-related signaling pathways (Review). , 2015, Oncology reports.

[77]  Yanju Ma,et al.  The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis , 2015, Oncotarget.

[78]  L. Chin,et al.  Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system , 2015, Cellular and Molecular Life Sciences.

[79]  A. Ciechanover.  The unravelling of the ubiquitin system , 2015, Nature Reviews Molecular Cell Biology.

[80]  M. Azuma,et al.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.

[81]  J. Gécz,et al.  La FAM fatale: USP9X in development and disease , 2015, Cellular and Molecular Life Sciences.

[82]  Aristotelis Tsirigos,et al.  FBXW7 modulates cellular stress response and metastatic potential via HSF1 post-translational modification , 2015, Nature Cell Biology.

[83]  Xin Liu,et al.  Colon cancer bears overexpression of OTUB1. , 2014, Pathology, research and practice.

[84]  Yanju Ma,et al.  Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells , 2014, Molecular Cancer.

[85]  K. Nakayama,et al.  Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells , 2014, British Journal of Cancer.

[86]  Jun Yu,et al.  CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancer. , 2014, Carcinogenesis.

[87]  Cuiping Liu,et al.  A Promoter Region Polymorphism in PDCD-1 Gene Is Associated with Risk of Rheumatoid Arthritis in the Han Chinese Population of Southeastern China , 2014, International journal of genomics.

[88]  Christopher E. Berndsen,et al.  New insights into ubiquitin E3 ligase mechanism , 2014, Nature Structural &Molecular Biology.

[89]  M. Gleave,et al.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer , 2014, Proceedings of the National Academy of Sciences.

[90]  S. Zheng,et al.  The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. , 2013, Immunity.

[91]  Yigang Zeng,et al.  Overexpression of RING box protein‐1 (RBX1) associated with poor prognosis of non‐muscle‐invasive bladder transitional cell carcinoma , 2013, Journal of surgical oncology.

[92]  Patrick G. A. Pedrioli,et al.  Ubiquitylation-dependent localization of PLK1 in mitosis , 2013, Nature Cell Biology.

[93]  W. Goessling,et al.  SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2 , 2012, The Journal of experimental medicine.

[94]  G. Kristiansen,et al.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma , 2012, Nature.

[95]  S. Bogaerts,et al.  Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. , 2011, The Journal of clinical investigation.

[96]  N. Donato,et al.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.

[97]  S. Broderick,et al.  SCCRO promotes glioma formation and malignant progression in mice. , 2010, Neoplasia.

[98]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[99]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[100]  J. Riley.  PD‐1 signaling in primary T cells , 2009, Immunological reviews.

[101]  J. Kappes,et al.  COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting. , 2009, The American journal of pathology.

[102]  Pier Paolo Pandolfi,et al.  The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network , 2008, Nature.

[103]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[104]  J. Yates,et al.  Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. , 2007, Nature.

[105]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[106]  Xin-Yuan Fu,et al.  CHIP Controls the Sensitivity of Transforming Growth Factor-β Signaling by Modulating the Basal Level of Smad3 through Ubiquitin-mediated Degradation* , 2005, Journal of Biological Chemistry.

[107]  J. Kato,et al.  Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3 , 2005, The EMBO journal.

[108]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[109]  Timothy Cardozo,et al.  Systematic analysis and nomenclature of mammalian F-box proteins. , 2004, Genes & development.

[110]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[111]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[112]  Keiji Tanaka,et al.  CHIP is a chaperone‐dependent E3 ligase that ubiquitylates unfolded protein , 2001, EMBO reports.

[113]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[114]  H. Nishina,et al.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b , 2000, Nature.

[115]  Jianping Zhou,et al.  MicroRNA-520b Functions as a Tumor Suppressor in Colorectal Cancer by Inhibiting Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1). , 2018, Oncology research.

[116]  C. Curran,et al.  PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. , 2017, Seminars in oncology.

[117]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[118]  T. O'Brien,et al.  Therapeutic strategies within the ubiquitin proteasome system , 2010, Cell Death and Differentiation.